Product image of Lenalidomide Cooper (Lenalidomide) supplied by GNH India

Lenalidomide Cooper

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Cooper (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Cooper, is a immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients, offering antineoplastic and anti‑angiogenic benefits.

GNH India supplies Lenalidomide Cooper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Manufacturer / TM Owner

Cooper Pharmaceuticals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma cells and dysplastic clones.

  • Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease.
  • Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia in patients with del(5q) cytogenetic abnormality.
  • Mantle Cell Lymphoma: enhances response rates when combined with rituximab in relapsed or refractory cases.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in reduced proliferation of malignant plasma cells, inhibition of angiogenesis, and modulation of cytokine production that enhances immune‑mediated tumor clearance.

Side Effects

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may require fluid replacement.
  • Nausea: upset stomach often occurring after dosing.
  • Rash: mild skin eruptions or itching.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: markedly reduced neutrophil count increasing infection risk.
  • Hepatotoxicity: elevated liver enzymes or liver injury.

Precautions & Warnings

When prescribing Lenalidomide, clinicians should consider several safety precautions.

  • Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception.
  • Thrombosis prophylaxis: assess need for anticoagulation in patients with risk factors.
  • Renal impairment: adjust monitoring and dosing in patients with reduced kidney function.
  • Hepatic function: monitor liver enzymes regularly during therapy.
  • Store at ambient temperature: keep tablets below 25°C in original container, protect from moisture and light.

Avoid Interactions

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may reduce Lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with Lenalidomide.

Moderate Interactions (Monitor Closely)

  • P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels.
  • Immunosuppressants (e.g., cyclosporine): heightened risk of infection.
  • Vaccines: live attenuated vaccines may be less effective; avoid during therapy.

Frequently Asked Questions

Lenalidomide Cooper is indicated for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes that have a del(5q) cytogenetic abnormality, and mantle cell lymphoma, typically in relapsed or refractory settings where other therapies have failed.

Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, changing its target profile. This triggers degradation of transcription factors Ikaros and Aiolos, which suppresses malignant plasma‑cell growth, reduces angiogenesis, and modulates immune responses to enhance tumor cell clearance.

The prescribed dose of Lenalidomide Cooper is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosage regimens are not standardized in public literature and must follow the prescriber’s written order.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while taking the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory agent derived from thalidomide. Compared with thalidomide, it generally offers greater potency, a more favorable side‑effect profile regarding peripheral neuropathy, and additional anti‑angiogenic activity, making it a preferred option for many hematologic cancers.

Store Lenalidomide Cooper tablets at ambient temperature, below 25 °C (77 °F). Keep the product in its original blister pack or container, protect it from moisture, excessive heat and direct sunlight to maintain stability throughout its shelf life.

Lenalidomide Cooper is taken orally as a tablet, usually with or without food, according to the dosing schedule prescribed by the healthcare professional. Patients should swallow the tablet whole and follow any specific timing instructions provided by their prescriber.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and hepatotoxicity indicated by marked elevations in liver enzymes. Prompt medical evaluation is required if any of these occur.

Lenalidomide Cooper should not be used by individuals who are pregnant, are unable to use effective contraception, have uncontrolled active infections, or have known hypersensitivity to lenalidomide or any of its excipients. Caution is also advised in patients with severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT